Literature DB >> 19513779

Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?

Paul R J Ames.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19513779     DOI： 10.1007/s10067-009-1210-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  20 in total

Review 1.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease.

Authors:  Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2003-05

2.  Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.

Authors:  F Ogawa; K Shimizu; E Muroi; T Hara; M Hasegawa; K Takehara; S Sato
Journal:  Rheumatology (Oxford)       Date:  2006-01-31       Impact factor: 7.580

3.  Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1.

Authors:  T Atsumi; M A Khamashta; R S Haworth; G Brooks; O Amengual; K Ichikawa; T Koike; G R Hughes
Journal:  Arthritis Rheum       Date:  1998-05

4.  8-Isoprostane-induced endothelin-1 production by infant rat pulmonary artery smooth muscle cells is mediated by Rho-kinase.

Authors:  Soojin L Yi; Crystal Kantores; Rosetta Belcastro; Judy Cabacungan; A Keith Tanswell; Robert P Jankov
Journal:  Free Radic Biol Med       Date:  2006-06-17       Impact factor: 7.376

5.  Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features.

Authors:  A Volpe; D Biasi; P Caramaschi; W Mantovani; L M Bambara; S Canestrini; M Ferrari; G Poli; M Degan; A Carletto; S Pieropan; P Minuz
Journal:  Rheumatology (Oxford)       Date:  2005-10-11       Impact factor: 7.580

6.  Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study.

Authors:  P R Ames; C Tommasino; J Alves; J D Morrow; L Iannaccone; G Fossati; S Caruso; F Caccavo; V Brancaccio
Journal:  Lupus       Date:  2000       Impact factor: 2.911

Review 7.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo.

Authors:  L J Roberts; J D Morrow
Journal:  Free Radic Biol Med       Date:  2000-02-15       Impact factor: 7.376

8.  Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

Authors:  C M Stein; S B Tanner; J A Awad; L J Roberts; J D Morrow
Journal:  Arthritis Rheum       Date:  1996-07

9.  Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.

Authors:  C P Denton; T D Bunce; M B Dorado; Z Roberts; H Wilson; K Howell; K R Bruckdorfer; C M Black
Journal:  Rheumatology (Oxford)       Date:  1999-04       Impact factor: 7.580

10.  A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome--a case series.

Authors:  Gisele Zandman-Goddard; Nurit Tweezer-Zaks; Tamar Shalev; Yair Levy; Michael Ehrenfeld; Pnina Langevitz
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691
View more
  2 in total

1.  Antiphospholipid antibodies and systemic scleroderma.

Authors:  Awa Oumar Touré; Fatimata Ly; Abibatou Sall; Alassane Diatta; Macoura Gadji; Moussa Seck; Blaise Faye; Tandakha Dieye; Saliou Diop
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

2.  Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients - a 24-month observation.

Authors:  Ewa Wielosz; Maria Majdan; Arkadiusz Koszarny; Magdalena Dryglewska; Jacek Tabarkiewicz
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.